Joint commercialization with Mochida Pharmaceutical of a dental pulp stem cell-based treatment for intestinal ganglion cell paucity
First written in FY2020. 5 of 7 entries say "Advanced", first in FY2025. Latest entry: 2026-08-13.
No other company in this theme has enough history to compare yet.
- 2026-08-13AdvancedEarnings presentation materials
「Kyushu University was newly selected for AMED's Research Project for Overcoming Pediatric Diseases (grant) to conduct a clinical study (April 2026).」
A new foundation for conducting the clinical study of intestinal ganglion cell deficiency was established through Kyushu University's selection by AMED. - FY2026AdvancedAnnual report
「For research and development on this disease, the company jointly applied with Kyushu University to the Japan Agency for Medical Research and Development (AMED)'s FY2026 Comprehensive Research Program for Overcoming Childhood Diseases, and the application was selected in March 2026.」
The joint application with Kyushu University for research and development on intestinal neuronal dysplasia was selected for AMED's FY2026 program in March 2026. - FY2025AdvancedAnnual report
「For research and development on this disease, the company jointly applied with Kyushu University to the Japan Agency for Medical Research and Development (AMED) program publicly solicited under the FY2025 "Comprehensive Research Program for Overcoming Childhood Diseases: Promotion of Perinatal and Pediatric Clinical Research and Development for Realizing Preventive Medicine," and the application was selected in April 2025.」
The joint application with Kyushu University for research and development on intestinal neuronal dysplasia was selected for an AMED program in April 2025. - FY2021-Q1RestatedAnnual report
「For dental pulp stem cells, the Company has had multiple academic institutions and companies assess their potential to provide new treatments in areas such as bone and neurological diseases by determining their suitability for treating diseases. During the previous consolidated fiscal year, the Company entered into joint research agreements with Showa University for bone-related diseases, Gifu Pharmaceutical University for eye-related diseases, and the Tokyo Metropolitan Institute of Medical Science, Nagoya University Hospital and Tokyo Medical and Dental University for cerebral palsy, as well as with Oita University for peripheral nerve paralysis and Nagoya University for spinal cord injuries. It also entered into a joint research and development agreement with ORTHOREBIRTH Co., Ltd. to create a treatment for cleft lip and palate, and a joint commercialisation agreement with Mochida Pharmaceutical Co.,Ltd. for regenerative medicine products for rare and intractable gastrointestinal diseases, including intestinal neuronal dysplasia. Research and development activities are being advanced under each agreement.」
The company continues research and development activities under its agreement with Mochida Pharmaceutical Co.,Ltd. for the joint commercialization of regenerative medicine products for intestinal neuronal dysplasia and other conditions. - FY2020First statedAnnual report
「In March 2020, the company entered into an agreement with Mochida Pharmaceutical Co.,Ltd. for the joint commercialization of regenerative medicine products for rare and intractable diseases in the gastrointestinal field, including intestinal neuronal dysplasia.」
The company entered into an agreement with Mochida Pharmaceutical Co.,Ltd. for the joint commercialization of regenerative medicine products for intestinal neuronal dysplasia and other conditions, combining its dental pulp stem cells with Mochida Pharmaceutical's expertise in the gastrointestinal field.